<DOC>
	<DOCNO>NCT00717925</DOCNO>
	<brief_summary>To assess tolerability initial safety profile Inotuzumab Ozogamicin ( CMC-544 ) patient B-Cell Non-Hodgkin 's Lymphoma ( NHL ) .</brief_summary>
	<brief_title>Study Evaluating Safety Tolerability Inotuzumab Ozogamicin ( CMC-544 ) Japanese Patients With B-cell Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>CD22positive , Bcell NHL progress 1 2 prior therapy . Patients progress least 1 prior chemotherapy regimen indolent lymphoma , 1/ 2 chemotherapy regimen , include anthracylin anthraquinon aggressive lymphoma . Eastern Cooperative Oncology Group ( ECOG ) performance status : 0/ 1 . Patients must receive monoclonal antibody radioimmunoconjugates within 3 month first dose test article . Patients must receive bilateral pelvic irradiation . Patients must receive chemotherapy , cancer immunosuppressive therapy , growth factor ( except erythropoietin ) , investigational agent within 4 week first dose test article .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>B-cell Non-Hodgkin 's Lymphoma</keyword>
	<keyword>NHL</keyword>
</DOC>